Navigating Therapeutic Pathways and Transforming Care in ATTR-CM - Episode 16
Future Directions in ATTR-CM
The panel concludes by discussing the future of ATTR-CM care. They highlight continued progress in disease-modifying therapies, with growing interest in determining how best to sequence or potentially combine treatments as evidence evolves. The group notes that as patients are diagnosed earlier, the goals of therapy may increasingly shift from slowing decline to preserving long-term function and quality of life. They emphasize the importance of expanding awareness and education across specialties so that more patients are recognized before advanced cardiac dysfunction develops. Improving access to therapy remains an essential area of focus, as cost and insurance barriers continue to influence treatment decisions. The panel also anticipates advances in monitoring disease progression, including the use of biomarkers and imaging to better assess response over time. Ultimately, the experts express optimism that ongoing research, broader recognition, and more refined care pathways will continue to improve outcomes for individuals living with ATTR-CM.
The panel concludes by discussing the future of ATTR-CM care. They highlight continued progress in disease-modifying therapies, with growing interest in determining how best to sequence or potentially combine treatments as evidence evolves. The group notes that as patients are diagnosed earlier, the goals of therapy may increasingly shift from slowing decline to preserving long-term function and quality of life.
They emphasize the importance of expanding awareness and education across specialties so that more patients are recognized before advanced cardiac dysfunction develops. Improving access to therapy remains an essential area of focus, as cost and insurance barriers continue to influence treatment decisions. The panel also anticipates advances in monitoring disease progression, including the use of biomarkers and imaging to better assess response over time.
Ultimately, the experts express optimism that ongoing research, broader recognition, and more refined care pathways will continue to improve outcomes for individuals living with ATTR-CM.
